Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Goserelin (Zoladex) vs Kisspeptin-10
An educational, source-based comparison of Goserelin (Zoladex) and Kisspeptin-10 — how each peptide works, what it's researched for, and what to know before going deeper.
Decapeptide GnRH agonist delivered via biodegradable subcutaneous implant. Suppresses gonadotropin and sex hormone production through pituitary desensitization.
- Prostate cancer
- Breast cancer (premenopausal)
- Endometriosis
- • FDA-approved.
- • Testosterone/estrogen flare; menopausal symptoms.
A peptide product of the KISS1 gene that acts upstream of GnRH neurons via the KISS1R/GPR54 receptor. Research demonstrates robust LH (and indirectly testosterone/estradiol) responses without desensitizing the pituitary.
- Hypothalamic amenorrhea
- Male hypogonadism research
- IVF triggering protocols
- • Investigational; not FDA-approved.
- • Effects on the HPG axis warrant physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Goserelin (Zoladex) | ZIPP trial | Lancet Oncology | 2005 | Adjuvant goserelin improved outcomes in premenopausal breast cancer. |
| Kisspeptin-10 | Kisspeptin-10 in reproductive endocrinology | Journal of Clinical Endocrinology & Metabolism | 2014 | Restored LH pulsatility in women with hypothalamic amenorrhea. |
Side-effect & safety grid
- FDA-approved.
- Testosterone/estrogen flare; menopausal symptoms.
- Investigational; not FDA-approved.
- Effects on the HPG axis warrant physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Goserelin (Zoladex) vs Kisspeptin-10 — Key differences
- Class: Goserelin (Zoladex) is classified as GnRH Agonist · Hormonal, while Kisspeptin-10 is Hormonal · HPG Axis.
- Primary research focus: Goserelin (Zoladex) — prostate cancer; Kisspeptin-10 — hypothalamic amenorrhea.
- Tag: FDA-Approved · Oncology vs Hormonal · HPG axis.